In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.
This study will examine the post-market performance of the Talent Thoracic Stent Graft System. This
study is a prospective non-randomized 5 year trial. A total of 451 subjects will be analyzed that consists of 195 enrolled subjects from the VALOR Test Group of the Talent Thoracic PMA Submission, and 256 new subjects to be enrolled following PMA approval.
Study Population Description
For purposes of cohort comparability, the inclusion/exclusion criteria will match to those used for the
VALOR study with the exception of the removal of the following two parameters from the exclusion criteria: the patient's access vessel (as determined by treating physician) precludes safe insertion of the delivery system and patient requires a planned aortic conduit. Patients diagnosed with a descending thoracic aortic aneurysm are considered candidates for the endovascular repair. ,
195 subjects from the VALOR Test Group of the Talent Thoracic PMA Submission, and 256
new implants, 26 sites
The primary endpoint of this study is freedom from aneurysm-related mortality at 5 years. The
postmarket performance of the Talent Thoracic Stent Graft System will be evaluated by comparing aneurysm-related mortality rates in patients implanted with the Talent Stent Graft System at 5 years versus the rate at 1 year for open surgery. The open surgery aneurysm-related mortality rate is based on the experience collected in 3 Centers of Excellence. Aneurysm-related mortality is defined as: Death from rupture of the thoracic aortic aneurysm or from any procedure intended to treat the descending thoracic aorta
Followup Visits and Length of Followup
The planned follow-up is 5 years for #2002-07. Participants from the #99-03 study will be
followed until the termination of the post-approval study.